Ozempic, Wegovy introduced in Kenya as diabetes, obesity burden grows

The introduction of Ozempic and Wegovy in Kenya is drawing attention to the country’s growing cardio-metabolic health burden, as healthcare experts call for a more comprehensive approach to the prevention and management of type 2 diabetes, obesity and related conditions. Novo..

✨ Key Highlights

Novo Nordisk has launched Ozempic and Wegovy in Kenya to address the rising burden of type 2 diabetes and obesity, amidst calls for a comprehensive healthcare approach.

Africa has seen a 142% rise in diabetes prevalence over the last decade.
Healthcare experts, including Dr Roseline Ngugi, stress the need for early diagnosis and integrated management of cardio-metabolic conditions.
Emphasis is placed on ensuring the affordability and accessibility of these new treatments for patients.